Trial Profile

A proof-of-concept Phase 2 clinical trial of KET-IR in treatment resistant bipolar depression (TR-BPD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ketamine (Primary)
Indications Bipolar depression; Treatment-resistant depressive disorder
Focus Proof of concept; Therapeutic Use
Sponsors Neurocentrx Pharma

Most Recent Events

23 Sep 2025 According to Neurocentrx Pharma media release, company plans to initiate the trial in first quarter of 2026
14 Dec 2023 New trial record
24 Oct 2023 According to Neurocentrx Pharma media release, In the first half of 2024, Neurocentrx plans to initiate this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com